Published in Pediatr Infect Dis on February 11, 1985
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
Epidemiology of chickenpox in England and Wales, 1967-85. Br Med J (Clin Res Ed) (1988) 2.07
Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr (2005) 1.14
The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect (1992) 1.14
Complications of varicella in a defined central European population. Arch Dis Child (1998) 1.01
The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ (2004) 1.00
Varicella zoster virus infections in Canadian children in the prevaccine era: A hospital-based study. Can J Infect Dis (1997) 0.93
Impact and costs of varicella prevention in a university hospital. Am J Public Health (1988) 0.89
Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol (2007) 0.88
Secular trends of chickenpox among military population in Israel in relation to introduction of varicella zoster vaccine 1979-2010. Hum Vaccin Immunother (2013) 0.86
Sudden death in childhood due to varicella pneumonia: a forensic case report with clinical implications. Int J Legal Med (2005) 0.84
The seroprevalence of varicella zoster antibodies in Behçet's and other skin diseases. Eur J Epidemiol (2003) 0.77
School and daycare exclusion policies for chickenpox: A rational approach. Paediatr Child Health (1999) 0.76
Acyclovir for treating varicella in otherwise healthy children and adolescents: a systematic review of randomised controlled trials. BMC Pediatr (2002) 0.75
Febrile Illness with Skin Rashes. Infect Chemother (2015) 0.75
Field evaluation of vaccine efficacy. Bull World Health Organ (1985) 4.95
Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 3.77
Rational strategy for rubella vaccination. Lancet (1983) 3.61
Measles vaccine efficacy in children previously vaccinated at 12 months of age. Pediatrics (1978) 2.98
Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health (1985) 2.58
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med (1989) 2.41
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA (1987) 2.28
A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol (1987) 2.13
Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. Am J Epidemiol (1989) 2.12
Continuing measles transmission in students despite school-based outbreak control program. Am J Epidemiol (1985) 2.09
Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J Epidemiol (1986) 1.93
From the Center for Disease control: current status of measles in the United States, 1973--1977. J Infect Dis (1978) 1.91
Progress in measles elimination. JAMA (1982) 1.87
Appropriate age for measles vaccination in the United States. Dev Biol Stand (1986) 1.80
Age-specific risks of varicella complications. Pediatrics (1981) 1.76
The resurgence of measles in the United States, 1989-1990. Annu Rev Med (1992) 1.72
The case for global eradication of poliomyelitis. Bull World Health Organ (1987) 1.72
Health impact of measles vaccination in the United States. Pediatrics (1985) 1.71
Current status of mumps and mumps vaccine in the United States. Pediatrics (1978) 1.71
Measles outbreak in a vaccinated school population: epidemiology, chains of transmission and the role of vaccine failures. Am J Public Health (1987) 1.70
Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J (1990) 1.70
Outbreak of paralytic poliomyelitis, Taiwan. Lancet (1984) 1.68
Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet (1990) 1.67
Epidemiology of pertussis, Atlanta, 1977. J Pediatr (1981) 1.62
Measles outbreak among unvaccinated preschool-aged children: opportunities missed by health care providers to administer measles vaccine. Pediatrics (1989) 1.57
Rubella vaccination in the United States: a ten-year review. Epidemiol Rev (1980) 1.53
An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease. Am J Epidemiol (1989) 1.53
Elimination of indigenous measles from the United States. Rev Infect Dis (1983) 1.50
Fetal risk associated with rubella vaccine: an update. Rev Infect Dis (1985) 1.50
Causes of low preschool immunization coverage in the United States. Annu Rev Public Health (1992) 1.45
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak. Am J Epidemiol (1995) 1.43
Varicella: complications and costs. Pediatrics (1986) 1.41
A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy. Public Health Rep (1992) 1.41
Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis (1970) 1.40
DTP vaccine litigation, 1988. Am J Dis Child (1990) 1.39
Measles surveillance--United States, 1991. MMWR CDC Surveill Summ (1992) 1.38
An epidemiological assessment of cholera control programs in rural East Pakistan. Int J Epidemiol (1972) 1.36
Increasing the supply of cadaveric kidneys for transplantation. Transplantation (1981) 1.35
Pertussis--a disease and a vaccine that are not going away. West J Med (1989) 1.35
Major impediments to measles elimination. The modern epidemiology of an ancient disease. Am J Dis Child (1985) 1.32
Increased lead absorption with anemia and slowed nerve conduction in children near a lead smelter. J Pediatr (1976) 1.32
Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics (1978) 1.30
Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. Am J Dis Child (1984) 1.26
Assessment of susceptibility to measles and rubella. JAMA (1982) 1.26
Universal immunization to interrupt rubella. Rev Infect Dis (1985) 1.25
Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis (1983) 1.24
A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J (1985) 1.24
Measles and rubella: our remaining responsibilities. Am J Public Health (1983) 1.23
Imported measles in the United States. JAMA (1982) 1.23
Pertussis epidemic in Oklahoma. Difficulties in preventing transmission. Am J Dis Child (1986) 1.23
Measles vaccines. Pediatr Clin North Am (1990) 1.21
Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs. 15 months. Am J Epidemiol (1982) 1.20
The opportunity and obligation to eliminate rubella from the United States. JAMA (1984) 1.20
Measles among the Amish: a comparative study of measles severity in primary and secondary cases in households. J Infect Dis (1991) 1.20
Clinical efficacy of rubella vaccine. Pediatr Infect Dis (1983) 1.18
Current status of mumps in the United States. J Infect Dis (1975) 1.17
A school-based measles outbreak: the effect of a selective revaccination policy and risk factors for vaccine failure. Am J Epidemiol (1990) 1.14
Deaths from varicella in infants. Pediatr Infect Dis (1985) 1.14
Crossing the divide from vaccine technology to vaccine delivery. The critical role of providers. JAMA (1994) 1.13
Preventing rubella: assessing missed opportunities for immunization. Am J Public Health (1987) 1.11
Some current issues relating to rubella vaccine. JAMA (1985) 1.10
Methods of assessing the impact of congenital rubella infection. Rev Infect Dis (1985) 1.10
Measles and measles vaccine efficacy in a remote island population. Bull World Health Organ (1982) 1.10
Impact of influenza A in a nursing home. JAMA (1982) 1.10
A benefit-cost analysis of mumps vaccine. Am J Dis Child (1982) 1.08
Mumps in the workplace. Further evidence of the changing epidemiology of a childhood vaccine-preventable disease. JAMA (1988) 1.07